ALK and neuroblastoma: In this basket trial, the ALK inhibitor ensartinib is under assessment in patients with relapsed or refractory NB among other solid tumours, non-Hodgkin’s lymphoma and histiocytic disorders with genetic alteration of ALK or ROS1 (NCT03213652).